TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Daré Bioscience ( (DARE) ).
On November 26, 2025, Daré Bioscience announced that Bayer HealthCare LLC will terminate their license agreement effective February 24, 2026, returning all rights to the investigational contraceptive Ovaprene to Daré. This move, due to Bayer’s strategic prioritization, allows Daré to fully control Ovaprene’s development and commercialization, strengthening its strategic position in the women’s health market. The ongoing Phase 3 clinical trial of Ovaprene continues with positive interim results and is supported by grant funding, with enrollment expected to complete in 2026. The return of rights enhances Daré’s strategic options, potentially attracting broad interest from pharmaceutical and consumer health sectors.
The most recent analyst rating on (DARE) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Underperform.
Daré Bioscience’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company’s ongoing financial distress, including negative equity and high liabilities, poses significant risks. Additionally, the stock’s technical indicators suggest bearish momentum, further weighing down the score. While the earnings call provided some positive insights into the company’s strategic initiatives, these are not enough to offset the financial and technical challenges.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Daré Bioscience is a health biotech company focused on closing the gap in women’s health by developing science-based solutions for contraception, menopause, pelvic pain, fertility, vaginal health, and infectious disease. The company aims to bring innovative, evidence-based therapies to market, emphasizing clinical rigor and regulatory compliance.
Average Trading Volume: 137,169
Technical Sentiment Signal: Strong Sell
Current Market Cap: $26.29M
Find detailed analytics on DARE stock on TipRanks’ Stock Analysis page.